NCT07265284 A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis
| NCT ID | NCT07265284 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. |
| Condition | Psoriasis |
| Study Type | INTERVENTIONAL |
| Enrollment | 104 participants |
| Start Date | 2025-12-03 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 104 participants in total. It began in 2025-12-03 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of IBI112 in the treatment of adolescent participants with moderate to severe plaque-type psoriasis.
Eligibility Criteria
Inclusion Criteria: Males or females aged 12 to 18 years; Diagnosed with plaque psoriasis and a history of psoriasis ≥6 months; suitable for phototherapy and/or systemic treatment for psoriasis. Exclusion Criteria: History of or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease Participant has history of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis Has received any therapeutic agent directly targeted to IL-17within 6 months of the first administration of study agent Has received any therapeutic agent directly targeted toTNF-a within 3 months of the first administration of study agent Has received any conventional therapeutic agent within 1 months of the first administration of study agent Has received any topic therapeutic agent within 2 weeks of the first administration of study agent Hsa received IBI112
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07265284 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, up to 18 Years, studying Psoriasis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07265284 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 104 participants.
Is NCT07265284 currently recruiting?
Yes, NCT07265284 is actively recruiting participants. Contact the research team at bingjing.feng@innoventbio.com for enrollment information.
Where is the NCT07265284 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07265284 clinical trial?
NCT07265284 is sponsored by Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.. The trial plans to enroll 104 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.